#Japan #FemTech #Kyoto #Flora #Nagase Industries

Nagase Industries' Strategic Investment in Flora

On April 27, 2026, Nagase Industries, headquartered in Chiyoda, Tokyo, announced a significant investment in Flora Inc., a cutting-edge FemTech startup based in Sakyo, Kyoto. This investment is part of a third-party share issuance by Flora, focusing on leveraging AI technologies to develop a specialized healthcare platform for women, aimed at addressing and visualizing gender-specific health challenges.

Flora is renowned for its innovative approach in the healthcare sector, utilizing advanced technologies to provide solutions that improve the well-being of women. The company is dedicated to offering well-being support services for female employees in organizations and personal AI healthcare applications for individual users, thus enhancing overall health and productivity.

This investment by Nagase Industries is facilitated through its wholly-owned subsidiary, Nagase Future Investments, channeling resources via their corporate venture capital (CVC) fund. By partnering with Flora, Nagase strives not only to support gender issues within its supply chain but also to contribute to building sustainable business models and promoting societal well-being.

Flora's Mission and Services

Flora focuses on developing an AI-driven healthcare platform that caters specifically to women’s health needs. Their services include:

• - Well-being support for female employees: Helping organizations implement programs that enhance the health and productivity of their female workforce.
• - AI healthcare applications: Providing individuals with accessible tools to manage their health using technology.

Such initiatives are designed to promote personal health while simultaneously enhancing productivity in the workplace, thus addressing the unique health challenges faced by women today.

The Vision for the Future

With this strategic investment, Nagase is committed to tackling gender-related challenges in the industry while continuing to create new values and solutions through material innovation. As the NAGASE Group states, they aim to solve manufacturing challenges through material technology, ensuring that their efforts not only address current needs but also anticipate future demands.

For further information about Flora and its groundbreaking work in FemTech, visit their official website.

Questions regarding this investment can be directed to Nagase Industries via their website here. Additionally, inquiries can be made through email at [email protected] for business-related questions or for media inquiries, interested parties can contact the Corporate Communication Division at Nagase Industries.

Flora, led by CEO Anna Kreshchenko, is poised for growth and innovation in the healthcare space, making this partnership between Nagase Industries and Flora a promising step towards building a sustainable future for women’s health initiatives.